ATE324456T1 - Proteinexpression in baculovirus-vektor expressionsystemen - Google Patents

Proteinexpression in baculovirus-vektor expressionsystemen

Info

Publication number
ATE324456T1
ATE324456T1 AT98962690T AT98962690T ATE324456T1 AT E324456 T1 ATE324456 T1 AT E324456T1 AT 98962690 T AT98962690 T AT 98962690T AT 98962690 T AT98962690 T AT 98962690T AT E324456 T1 ATE324456 T1 AT E324456T1
Authority
AT
Austria
Prior art keywords
expression
baculovirus vector
systems
protein expression
protein
Prior art date
Application number
AT98962690T
Other languages
English (en)
Inventor
Dietmar Kretzdorn
De Wiel Dirk Franciscus Ma Van
Smit Abraham Johannes De
Robertus Jacobus Mari Moormann
Erik Kees Hamann
Original Assignee
Stichting Inst Voor Dierhouder
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8229076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324456(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Inst Voor Dierhouder, Bayer Ag filed Critical Stichting Inst Voor Dierhouder
Application granted granted Critical
Publication of ATE324456T1 publication Critical patent/ATE324456T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98962690T 1997-12-18 1998-12-17 Proteinexpression in baculovirus-vektor expressionsystemen ATE324456T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97203989A EP0924298A1 (de) 1997-12-18 1997-12-18 Proteinexpression in Baculovirus-vektor Expressionsystemen

Publications (1)

Publication Number Publication Date
ATE324456T1 true ATE324456T1 (de) 2006-05-15

Family

ID=8229076

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962690T ATE324456T1 (de) 1997-12-18 1998-12-17 Proteinexpression in baculovirus-vektor expressionsystemen

Country Status (21)

Country Link
US (2) US6555346B1 (de)
EP (2) EP0924298A1 (de)
JP (2) JP4220126B2 (de)
KR (3) KR100796871B1 (de)
CN (2) CN1283801C (de)
AR (1) AR015499A1 (de)
AT (1) ATE324456T1 (de)
AU (1) AU750514B2 (de)
BR (1) BR9813692B1 (de)
CA (2) CA2315248C (de)
CO (1) CO4820445A1 (de)
DE (1) DE69834346T2 (de)
DK (1) DK1049788T3 (de)
ES (1) ES2267203T3 (de)
HU (1) HU228122B1 (de)
IL (2) IL136815A0 (de)
NZ (1) NZ505322A (de)
TW (1) TWI225094B (de)
UY (1) UY25315A1 (de)
WO (1) WO1999031257A2 (de)
ZA (1) ZA9811434B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6926846B1 (en) 1996-08-08 2005-08-09 Pactiv Corporation Methods of using an oxygen scavenger
EP0924298A1 (de) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Proteinexpression in Baculovirus-vektor Expressionsystemen
EP1035205A1 (de) 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Sich nicht verbreitendes Pestivirus
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
CN1338310A (zh) * 2000-08-10 2002-03-06 清华大学 一种猪瘟病毒表位疫苗及其制备方法
AU2002248557A1 (en) * 2001-03-05 2002-09-19 Transtech Pharma, Inc. High level insect expression of rage proteins
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
CN102212019B (zh) * 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (de) * 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
MXPA05011832A (es) 2003-05-09 2006-02-17 Neose Technologies Inc Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
AU2004293103C1 (en) * 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1694274B1 (de) * 2003-12-03 2013-04-24 BioGeneriX AG Glykopegylierter Granulocyten-Kolonie-stimulierender Faktor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US8361961B2 (en) * 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1799249A2 (de) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2284191A3 (de) 2004-12-22 2011-07-20 Ambrx, Inc. Prozess zur Herstellung von hGH
WO2006071840A2 (en) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006068802A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006078645A2 (en) * 2005-01-19 2006-07-27 Neose Technologies, Inc. Heterologous polypeptide expression using low multiplicity of infection of viruses
EP1866427A4 (de) * 2005-03-30 2010-09-01 Novo Nordisk As Herstellungsverfahren zur produktion von in insektenzelllinien entstandenen peptiden
EP1871795A4 (de) * 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
EP1888098A2 (de) * 2005-05-25 2008-02-20 Neose Technologies, Inc. Glykopegylierte erythropoetin-formulierungen
CA2609205A1 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090305967A1 (en) * 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
CN100497612C (zh) * 2006-01-25 2009-06-10 中国农业科学院生物技术研究所 一种耐高温乳糖酶的制备方法
CU23544A1 (es) 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
PT2061878E (pt) 2006-09-08 2014-04-22 Ambrx Inc Supressor híbrido arnt para células de vertebrados
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CA2665480C (en) * 2006-10-04 2019-11-12 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
WO2008073620A2 (en) * 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
EP2076533B1 (de) 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
WO2008154639A2 (en) * 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101152570B (zh) * 2007-10-19 2010-11-24 清华大学 一种猪瘟病毒表位疫苗及其制备方法
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
PL2318029T3 (pl) 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
TWI362416B (en) * 2008-07-31 2012-04-21 Mao Xing Biolog Technology Co Ltd Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
EP2202298A1 (de) 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Rekombinantes Virus der klassischen Schweinepest (KSP) mit einem modifizierten E2-Protein und Verfahren zur Erzeugung des besagten Klassiche-Schweinepest-Virus
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
JP6080850B2 (ja) * 2011-08-24 2017-02-15 ゾエティス・サービシーズ・エルエルシー 改善されたワクチン診断法
RU2619161C2 (ru) * 2012-06-12 2017-05-12 Альтернативе Гене Экспрессион С.Л. Элементы рекомбинантной днк для экспрессии рекомбинантных белков в клетке-хозяине
JP6063563B2 (ja) * 2012-06-12 2017-01-18 オルタナティブ ジーン エクスプレッション エセ．エレ． 宿主昆虫における組換えタンパク質の発現のためのバキュロウイルスｄｎａエレメント
CA2903811A1 (en) 2013-03-15 2014-09-25 Spectrum Brands, Inc. Electro-mechanical locks with bezel turning function
DE102013103336A1 (de) * 2013-04-03 2014-10-09 B. Braun Avitum Ag Vorrichtung zur Identifizierung einer Dialysatorvorrichtung oder einer Komponente derselben, und hierfür verwendbare Sensorvorrichtung
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
WO2015028546A1 (en) * 2013-08-30 2015-03-05 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN103882051B (zh) * 2014-03-20 2016-04-06 北京市农林科学院 一种检测猪瘟病毒抗体的elisa方法及检测试剂盒
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20170083249A (ko) * 2016-01-08 2017-07-18 경상대학교산학협력단 곤충세포를 이용한 식물 유래 오스모틴 단백질의 대량 생산 방법
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
AU2019290228A1 (en) 2018-06-22 2021-01-28 AskBio Inc. Vectors for gene delivery that persist within cells
CN109182380B (zh) * 2018-08-14 2022-06-03 浙江大学 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
CN112646840B (zh) * 2020-12-25 2022-11-18 石河子大学 一种杆状病毒表达系统制备牛病毒性腹泻病毒e2蛋白的方法及应用
EP4377466A4 (de) * 2021-07-28 2025-11-05 Biomarin Pharm Inc Grossskalige adeno-assoziierte virus-herstellungssysteme
US20250051820A1 (en) 2021-12-27 2025-02-13 Denka Company Limited Method for producing protein in baculovirus expression system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA901719B (en) * 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5514634A (en) 1991-11-06 1996-05-07 Mobil Oil Corporation High activity polyethylene catalysts
CN101255433A (zh) * 1994-06-17 2008-09-03 动物保健研究所 瘟病毒株的核苷酸序列,由这些序列编码的多肽及其在诊断和预防瘟病毒感染中的应用
JPH09509682A (ja) * 1994-12-20 1997-09-30 アクゾ・ノベル・エヌ・ベー ペスチウイルスのｔ細胞刺激性タンパク質
EP0842275A1 (de) * 1995-02-17 1998-05-20 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) HERSTELLUNG EINES BIOLOGISCH AKTIVEM,REKOMBINANTEN RINDER FOLLIKEL STIMULIERENDEN HORMONS(REC bFSH) IM BACULOVIRUS EXPRESSIONS-SYSTEM
EP0924298A1 (de) * 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Proteinexpression in Baculovirus-vektor Expressionsystemen

Also Published As

Publication number Publication date
HUP0101136A2 (hu) 2001-08-28
HUP0101136A3 (en) 2010-01-28
IL181468A (en) 2010-12-30
KR100699609B1 (ko) 2007-03-27
CN101130073A (zh) 2008-02-27
ZA9811434B (en) 1999-06-16
CA2635158A1 (en) 1999-06-24
KR20050115340A (ko) 2005-12-07
TWI225094B (en) 2004-12-11
BR9813692B1 (pt) 2011-03-09
DK1049788T3 (da) 2006-08-28
EP1049788B1 (de) 2006-04-26
IL181468A0 (en) 2007-07-04
JP4220126B2 (ja) 2009-02-04
WO1999031257A3 (en) 1999-08-26
AU750514B2 (en) 2002-07-18
US6555346B1 (en) 2003-04-29
BR9813692A (pt) 2001-11-13
CA2315248C (en) 2008-10-14
ES2267203T3 (es) 2007-03-01
KR20010033304A (ko) 2001-04-25
CO4820445A1 (es) 1999-07-28
UY25315A1 (es) 1999-09-27
DE69834346T2 (de) 2007-04-19
EP0924298A1 (de) 1999-06-23
HU228122B1 (en) 2012-11-28
KR20050115341A (ko) 2005-12-07
KR100796871B1 (ko) 2008-01-22
DE69834346D1 (en) 2006-06-01
AR015499A1 (es) 2001-05-02
JP2007254482A (ja) 2007-10-04
CN1283801C (zh) 2006-11-08
KR100682171B1 (ko) 2007-02-12
HK1037670A1 (en) 2002-02-15
JP4336723B2 (ja) 2009-09-30
IL136815A0 (en) 2001-06-14
US20040028701A1 (en) 2004-02-12
US6919085B2 (en) 2005-07-19
WO1999031257A2 (en) 1999-06-24
CN1295620A (zh) 2001-05-16
CA2315248A1 (en) 1999-06-24
EP1049788A2 (de) 2000-11-08
AU1786599A (en) 1999-07-05
JP2003533964A (ja) 2003-11-18
NZ505322A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE324456T1 (de) Proteinexpression in baculovirus-vektor expressionsystemen
EE200000148A (et) Kay - uus immuunsüsteemi valk
NO20002677D0 (no) Polyeteresteramider
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
NO983364D0 (no) Konsensusproteiner
ID24289A (id) Benzotiazol inhibitor-inhibitor protein terosin kinase
NO20002990L (no) Nytt overflateprotein
DE69839603D1 (de) Zierenden proteins
DE69840111D1 (de) Bankautomat
ID20560A (id) Pakaian sekali pakai
DE59801355D1 (de) Schere
DE69817671D1 (de) Antragsrolle
NO985680D0 (no) Peptidderivater
NO983849L (no) Peptidderivater
EP1018551A4 (de) Megsin-protein
ATE295417T1 (de) Angiostatin-bindendes protein
GB9715064D0 (en) Protein expression
TR199701666A3 (tr) Sismanliga karsi proteinler
DE69830081D1 (de) Zwischenstück
ATE235511T1 (de) Vielfältig verzweigte peptidkonstruktionen
BR9700300A (pt) Aperfeiçoamentos em termostatos
KR980000586U (ko) 수저통
ATA188297A (de) Beschlag
ITMI972543A1 (it) Proteina p27bbp
DK1017798T3 (da) Lunasinpeptider

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1049788

Country of ref document: EP